About Alimera Sciences (NASDAQ:ALIM)
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALIM
CUSIPN/A
Phone678-990-5740
Debt
Debt-to-Equity Ratio-0.64%
Current Ratio4.07%
Quick Ratio3.91%
Price-To-Earnings
Trailing P/E Ratio-3.86
Forward P/E Ratio-18.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$35.91 million
Price / Sales2.18
Cash FlowN/A
Price / CashN/A
Book Value($0.78) per share
Price / Book-1.44
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-22,000,000.00
Net Margins-61.26%
Return on EquityN/A
Return on Assets-30.26%
Miscellaneous
Employees126
Outstanding Shares69,990,000
Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions
What is Alimera Sciences' stock symbol?
Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."
How were Alimera Sciences' earnings last quarter?
Alimera Sciences (NASDAQ:ALIM) released its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.07. The biopharmaceutical company earned $9.14 million during the quarter, compared to analysts' expectations of $9.60 million. View Alimera Sciences' Earnings History.
When is Alimera Sciences' next earnings date?
What price target have analysts set for ALIM?
3 equities research analysts have issued 12 month price targets for Alimera Sciences' stock. Their predictions range from $3.00 to $5.00. On average, they anticipate Alimera Sciences' share price to reach $4.00 in the next twelve months. View Analyst Ratings for Alimera Sciences.
What are Wall Street analysts saying about Alimera Sciences stock?
Here are some recent quotes from research analysts about Alimera Sciences stock:
- 1. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (4/10/2018)
- 2. Cowen Inc analysts commented, "Adaptimmune reported Q3 financials including net loss of $1MM and a cash balance." (11/2/2017)
Who are some of Alimera Sciences' key competitors?
Some companies that are related to Alimera Sciences include Tetraphase Pharmaceuticals (TTPH), Acer Therapeutics (ACER), Sierra Oncology (SRRA), Aeglea Bio Therapeutics (AGLE), Aldeyra Therapeutics (ALDX), BioXcel Therapeutics (BTAI), Affimed (AFMD), Zynerba Pharmaceuticals (ZYNE), BioDelivery Sciences International (BDSI), Checkpoint Therapeutics (CKPT), Adamis Pharmaceuticals (ADMP), Galectin Therapeutics (GALT), Axovant Sciences (AXON), AcelRx Pharmaceuticals (ACRX), Otonomy (OTIC), Bellerophon Therapeutics (BLPH), ContraFect (CFRX) and Trevena (TRVN).
Who are Alimera Sciences' key executives?
Alimera Sciences' management team includes the folowing people:
- Richard S. Eiswirth Jr., President, Chief Financial Officer (Age 47)
- Rich Cockrell, President
- C. Daniel Myers, Chief Executive Officer (Age 62)
- Kenneth E. Green Ph.D., Senior Vice President, Chief Scientific Officer (Age 57)
- David R. Holland, Senior Vice President - Sales and Marketing (Age 52)
- Philip Ashman, Senior Vice President, European Managing Director (Age 51)
- Mark J. Brooks, Independent Director (Age 48)
- Brian K. Halak Ph.D., Independent Director (Age 45)
- Peter J. Pizzo III, Independent Director (Age 49)
Has Alimera Sciences been receiving favorable news coverage?
News stories about ALIM stock have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alimera Sciences earned a media sentiment score of 0.04 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.65 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Alimera Sciences?
Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alimera Sciences' stock price today?
One share of ALIM stock can currently be purchased for approximately $1.12.
How big of a company is Alimera Sciences?
Alimera Sciences has a market capitalization of $78.38 million and generates $35.91 million in revenue each year. The biopharmaceutical company earns $-22,000,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Alimera Sciences employs 126 workers across the globe.
How can I contact Alimera Sciences?
Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]
MarketBeat Community Rating for Alimera Sciences (ALIM)
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alimera Sciences (NASDAQ:ALIM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Alimera Sciences in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 257.14%. The high price target for ALIM is $5.00 and the low price target for ALIM is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.00 | $4.00 | $4.00 | $4.00 |
| Price Target Upside: | 257.14% upside | 233.33% upside | 222.58% upside | 185.71% upside |
Alimera Sciences (NASDAQ:ALIM) Consensus Price Target History
Alimera Sciences (NASDAQ:ALIM) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Alimera Sciences (NASDAQ:ALIM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Alimera Sciences (NASDAQ ALIM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.70%
Institutional Ownership Percentage: 46.11%
Alimera Sciences (NASDAQ ALIM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/6/2018 | Armistice Capital Master Fund | Major Shareholder | Buy | 20,000 | $1.14 | $22,800.00 | |  |
| 2/2/2018 | Armistice Capital, Llc | Major Shareholder | Buy | 8,000 | $1.16 | $9,280.00 | | |
| 1/19/2018 | C. Daniel Myers | CEO | Sell | 52,900 | $1.20 | $63,480.00 | 101,511 | |
| 1/19/2018 | Philip Ashman | SVP | Sell | 25,500 | $1.20 | $30,600.00 | 12,750 | |
| 1/19/2018 | Richard S Eiswirth Jr | Insider | Sell | 13,410 | $1.20 | $16,092.00 | 84,779 | |
| 1/17/2018 | C. Daniel Myers | CEO | Sell | 52,900 | $1.23 | $65,067.00 | 154,411 | |
| 1/17/2018 | Philip Ashman | SVP | Sell | 25,500 | $1.23 | $31,365.00 | 38,250 | |
| 1/17/2018 | Richard S Eiswirth Jr | Insider | Sell | 14,494 | $1.23 | $17,827.62 | 98,619 | |
| 3/10/2017 | C. Daniel Myers | CEO | Sell | 21,172 | $1.39 | $29,429.08 | 180,861 | |
| 9/15/2016 | Richard S Eiswirth Jr | Insider | Sell | 51,471 | $1.51 | $77,721.21 | 86,445 | |
| 4/21/2016 | L.P. Bavp | Major Shareholder | Sell | 478,673 | $2.59 | $1,239,763.07 | 4,477,291 | |
| 12/16/2015 | Richard S. Eiswirth, Jr. | CFO | Sell | 46,669 | $2.31 | $107,805.39 | 34,974 | |
| 12/8/2015 | James E Flynn | Insider | Buy | 272,249 | $3.01 | $819,469.49 | | |
| 12/3/2015 | James E Flynn | Insider | Buy | 243,252 | $3.00 | $729,756.00 | | |
| 10/30/2015 | James E Flynn | Insider | Buy | 16,542 | $3.00 | $49,626.00 | | |
| 10/28/2015 | James E Flynn | Insider | Buy | 59,342 | $3.00 | $178,026.00 | | |
| 10/26/2015 | James E Flynn | Insider | Buy | 60,364 | $3.00 | $181,092.00 | | |
| 10/21/2015 | James E Flynn | Major Shareholder | Buy | 160,684 | $3.00 | $482,052.00 | | |
| 10/20/2015 | James E Flynn | Major Shareholder | Buy | 100,130 | $3.00 | $300,390.00 | | |
| 10/19/2015 | James E Flynn | Major Shareholder | Buy | 129,226 | $2.92 | $377,339.92 | | |
| 10/15/2015 | Richard S. Eiswirth, Jr. | CFO | Sell | 13,625 | $2.69 | $36,651.25 | 34,974 | |
| 10/9/2015 | James E Flynn | Insider | Buy | 321,785 | $2.42 | $778,719.70 | | |
| 9/3/2015 | Calvin W Roberts | Director | Buy | 6,424 | $3.00 | $19,272.00 | 6,389 | |
| 8/21/2015 | Kenneth Green | SVP | Sell | 20,000 | $3.29 | $65,800.00 | 48,235 | |
| 8/17/2015 | Kenneth Green | SVP | Sell | 20,000 | $3.90 | $78,000.00 | 68,235 | |
| 6/26/2015 | L.P. Bavp | Major Shareholder | Sell | 1,024 | $5.00 | $5,120.00 | | |
| 6/19/2015 | L.P. Bavp | Major Shareholder | Sell | 5,568 | $5.00 | $27,840.00 | | |
| 5/1/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $4.37 | $8,740.00 | | |
| 4/27/2015 | L.P. Bavp | Major Shareholder | Sell | 3,114 | $5.02 | $15,632.28 | | |
| 4/23/2015 | L.P. Bavp | Major Shareholder | Sell | 4,362 | $5.00 | $21,810.00 | | |
| 4/20/2015 | L.P. Bavp | Major Shareholder | Sell | 30,300 | $5.03 | $152,409.00 | | |
| 4/15/2015 | L.P. Bavp | Major Shareholder | Sell | 35,800 | $5.03 | $180,074.00 | | |
| 4/14/2015 | L.P. Bavp | Major Shareholder | Sell | 18,400 | $5.01 | $92,184.00 | | |
| 4/13/2015 | L.P. Bavp | Major Shareholder | Sell | 100 | $5.00 | $500.00 | | |
| 3/6/2015 | Richard S Eiswirth Jr | CFO | Buy | 10,000 | $4.84 | $48,400.00 | | |
| 3/2/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $5.21 | $10,420.00 | | |
| 1/2/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $5.51 | $11,020.00 | | |
| 1/2/2015 | David Holland | SVP | Sell | 5,000 | $5.56 | $27,800.00 | | |
| 12/1/2014 | C. Daniel Myers | CEO | Sell | 2,000 | $5.99 | $11,980.00 | | |
| 12/1/2014 | David Holland | SVP | Sell | 5,000 | $5.71 | $28,550.00 | | |
| 10/27/2014 | L.P. Bavp | Major Shareholder | Sell | 57,918 | $6.34 | $367,200.12 | | |
| 10/1/2014 | C. Daniel Myers | CEO | Sell | 2,000 | $5.42 | $10,840.00 | | |
| 10/1/2014 | David Holland | SVP | Sell | 5,000 | $5.26 | $26,300.00 | | |
| 10/1/2014 | Patrick Lee | Major Shareholder | Sell | 621,191 | $5.42 | $3,366,855.22 | | |
| 9/30/2014 | Patrick Lee | Major Shareholder | Sell | 354,062 | $5.42 | $1,919,016.04 | | |
| 9/29/2014 | Patrick Lee | Major Shareholder | Sell | 240,662 | $5.47 | $1,316,421.14 | | |
| 9/11/2014 | L.P. Bavp | Major Shareholder | Sell | 2,816 | $6.25 | $17,600.00 | | |
| 9/4/2014 | L.P. Bavp | Major Shareholder | Sell | 39,500 | $6.33 | $250,035.00 | | |
| 8/29/2014 | L.P. Bavp | Major Shareholder | Sell | 7,400 | $6.27 | $46,398.00 | | |
| 8/28/2014 | L.P. Bavp | Major Shareholder | Sell | 3,000 | $6.27 | $18,810.00 | | |
| 8/1/2014 | David Holland | SVP | Sell | 5,000 | $5.64 | $28,200.00 | | |
| 7/1/2014 | David Holland | SVP | Sell | 5,000 | $6.02 | $30,100.00 | | |
| 5/1/2014 | David Holland | SVP | Sell | 5,000 | $5.93 | $29,650.00 | | |
| 3/4/2014 | C. Daniel Myers | CEO | Sell | 22,775 | $7.10 | $161,702.50 | | |
| 3/4/2014 | David Holland | SVP | Sell | 10,000 | $6.84 | $68,400.00 | | |
| 3/4/2014 | Susan Caballa | Insider | Sell | 8,931 | $7.01 | $62,606.31 | | |
| 1/16/2014 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 296,760 | $6.39 | $1,896,296.40 | | |
| 7/17/2013 | Polaris Venture Management Co | Insider | Sell | 122,937 | $4.80 | $590,097.60 | | |
| 6/20/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 10,516 | $5.01 | $52,685.16 | | |
| 6/19/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 55,278 | $5.39 | $297,948.42 | | |
| 6/18/2013 | Polaris Venture Management Co | Insider | Sell | 37,063 | $5.44 | $201,622.72 | | |
| 6/17/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 126,709 | $5.29 | $670,290.61 | | |
| 6/11/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 5,337 | $5.00 | $26,685.00 | | |
| 5/17/2013 | David Holland | SVP | Sell | 30,000 | $4.13 | $123,900.00 | | |
| 5/16/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 44,242 | $4.60 | $203,513.20 | | |
| 12/13/2012 | Peter J Pizzo III | Director | Buy | 5,000 | $1.44 | $7,200.00 | | |
| 12/3/2012 | C. Daniel Myers | CEO | Sell | 7,700 | $1.95 | $15,015.00 | | |
(Data available from 1/1/2013 forward)
Alimera Sciences (NASDAQ ALIM) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | HC Wainwright Analysts Give Alimera Sciences (ALIM) a $5.00 Price Target
www.americanbankingnews.com - April 19 at 12:16 PM |
| Alimera Sciences (ALIM) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - April 18 at 4:44 PM |
| Alimera Sciences (ALIM) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 15 at 8:22 PM |
| Cowen Reiterates $3.00 Price Target for Alimera Sciences (ALIM)
www.americanbankingnews.com - April 15 at 8:22 PM |
| Alimera Sciences (ALIM) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - April 15 at 7:48 PM |
| Zacks Investment Research Upgrades Alimera Sciences (ALIM) to Buy
www.americanbankingnews.com - April 10 at 8:41 AM |
| Alimera Sciences (ALIM) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 2 at 4:46 PM |
| Alimera Sciences (ALIM) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - April 1 at 1:26 AM |
| Alimera Sciences (ALIM) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 4:32 PM |
| Zacks Investment Research Lowers Alimera Sciences (ALIM) to Hold
www.americanbankingnews.com - March 23 at 4:34 PM |
| Alimera Sciences (ALIM) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 22 at 4:32 PM |
 | Edited Transcript of ALIM earnings conference call or presentation 1-Mar-18 2:00pm GMT
finance.yahoo.com - March 18 at 10:01 AM |
| Stonepine Capital Management LLC Grows Position in Alimera Sciences Inc (ALIM)
www.americanbankingnews.com - March 6 at 10:02 AM |
 | Global Diabetic Retinopathy Market Anticipated Growth By Increasing Incidence of Ophthalmic Complications in Diabetic Patients
www.marketwatch.com - March 5 at 10:42 AM |
 | Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 2 at 4:22 PM |
| Alimera Sciences (ALIM) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS
www.americanbankingnews.com - March 1 at 11:18 AM |
| Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 9:41 AM |
| Alimera Sciences, Inc. to Host Earnings Call
finance.yahoo.com - March 1 at 9:41 AM |
| Alimera Sciences to Present at the 38th Annual Cowen & Co. Health Care Conference
finance.yahoo.com - February 27 at 10:15 AM |
| Head to Head Comparison: Argos Therapeutics (ARGS) versus Alimera Sciences (ALIM)
www.americanbankingnews.com - February 25 at 1:10 AM |
| Alimera Sciences (ALIM) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 3:46 AM |
| Alimera Sciences to Report Fourth Quarter and Full Year 2017 Results on February 28, 2018
finance.yahoo.com - February 14 at 3:24 PM |
| Alimera Sciences, Inc. (ALIM) Major Shareholder Armistice Capital Master Fund Buys 20,000 Shares
www.americanbankingnews.com - February 9 at 9:08 PM |
| Alimera Sciences (ALIM) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - January 22 at 11:54 PM |
| Insider Selling: Alimera Sciences, Inc. (ALIM) SVP Sells 25,500 Shares of Stock
www.americanbankingnews.com - January 19 at 10:50 PM |
| Insider Selling: Alimera Sciences, Inc. (ALIM) Insider Sells 13,410 Shares of Stock
www.americanbankingnews.com - January 19 at 10:50 PM |
| Alimera Sciences, Inc. (ALIM) CEO C. Daniel Myers Sells 52,900 Shares
www.americanbankingnews.com - January 19 at 10:30 PM |
| Alimera Sciences, Inc. (ALIM) Insider Sells $17,827.62 in Stock
www.americanbankingnews.com - January 18 at 8:30 PM |
| Philip Ashman Sells 25,500 Shares of Alimera Sciences, Inc. (ALIM) Stock
www.americanbankingnews.com - January 18 at 8:30 PM |
| Insider Selling: Alimera Sciences, Inc. (ALIM) CEO Sells 52,900 Shares of Stock
www.americanbankingnews.com - January 18 at 8:00 PM |
| Strongbridge Biopharma (SBBP) vs. Alimera Sciences (ALIM) Critical Review
www.americanbankingnews.com - January 10 at 8:02 AM |
| Alimera Sciences (ALIM) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - January 8 at 9:26 PM |
 | BRIEF-Alimera Sciences Enters Into $40 Mln Term Loan Agreement With Solar Capital
www.reuters.com - January 8 at 3:43 PM |
| Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital - GlobeNewswire (press release)
globenewswire.com - January 8 at 8:33 AM |
| Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital
finance.yahoo.com - January 8 at 8:33 AM |
 | Alimera Sciences (ALIM) Announces Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior ... - StreetInsider.com
www.streetinsider.com - January 5 at 3:40 PM |
| Alimera Sciences (ALIM) Announces Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior Uveitis Indication in Europe
www.streetinsider.com - January 4 at 3:38 PM |
| Alimera Sciences Receives Acceptance of Filing to Obtain Approval for ILUVIEN® Non-Infectious Posterior Uveitis Indication in Europe
finance.yahoo.com - January 4 at 11:14 AM |
| Alimera Sciences (ALIM) Raised to Sell at ValuEngine
www.americanbankingnews.com - December 31 at 2:58 PM |
| ETFs with exposure to Alimera Sciences, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 3:37 PM |
| Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland
finance.yahoo.com - December 11 at 12:04 PM |
| ETFs with exposure to Alimera Sciences, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 3:37 PM |
| Head to Head Analysis: Alimera Sciences (ALIM) and Novus Therapeutics (NVUS)
www.americanbankingnews.com - December 7 at 1:16 PM |
| Reviewing Fortress Biotech (FBIO) & Alimera Sciences (ALIM)
www.americanbankingnews.com - December 4 at 7:39 PM |
| Alimera Sciences (ALIM) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - December 3 at 6:30 AM |
| Alimera Sciences to Present at the 10th Annual LD Micro Conference
finance.yahoo.com - November 28 at 3:36 PM |
| Alimera Sciences, Inc. (ALIM) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - November 27 at 5:28 PM |
| Alimera Sciences, Inc. (ALIM) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - November 22 at 4:26 PM |
| ETFs with exposure to Alimera Sciences, Inc. : November 21, 2017
finance.yahoo.com - November 21 at 4:15 PM |
| Zacks: Alimera Sciences, Inc. (ALIM) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 14 at 1:30 PM |
Alimera Sciences (NASDAQ:ALIM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alimera Sciences (NASDAQ:ALIM) Income Statement, Balance Sheet and Cash Flow Statement
Alimera Sciences (NASDAQ ALIM) Stock Chart for Friday, April, 20, 2018
Loading chart…
